Under this collaborative agreement,
The PanCancer IO 360 Panel assays key pathways from the tumor, the microenvironment and the immune system and includes more than 20 signatures that are potentially associated with therapeutic response to novel therapeutic agents with "matched" mechanisms of action. These signatures include defective DNA mismatch repair (dMMR) - the genetic abnormality causing high microsatellite instability (MSI-H), which is particularly relevant in this tumor type and is associated with high response to PD-1/PD-L1 blockade. Interrogation of colorectal tumor samples from the NSABP repository with the PanCancer IO 360 Panel will test the concordance between dMMR status as assessed by the NanoString PanCancer IO 360 Panel and the standard immunohistochemistry (IHC) approach.
The collaborators will use the PanCancer IO 360 Panel to explore biological pathways of immune resistance including NanoString's Tumor Inflammation Signature (TIS), recently described by Ayers, et al. (https://www.jci.org/articles/view/91190), which measures the presence or absence of a peripherally suppressed adaptive immune response within the tumor. For example, TIS was found to be predictive of response to pembrolizumab, and pembrolizumab's mechanism of action is believed to unleash a pre-existent adaptive immune response by inactivating the inhibitory activity of this receptor.
"Anti-PD-1 and anti-PD-L1 antibodies have demonstrated significantly durable efficacy in patients with metastatic MSI-H colorectal cancer. Unfortunately, this subset of patients represents only about 5% of stage IV CRC patients, leaving the vast majority of this population in great need of effective treatments," said
"It is critical to find better
ways of identifying colorectal cancer patients who will benefit from current immunotherapeutic approaches as well as improving our understanding of the mechanisms of resistance at the molecular level," said Dr.
For more information, please visit www.nanostring.com.
About the NSABP
The NSABP, headquartered in
Forward-Looking Statements -
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the outcomes of the research collaboration between
For more information, please visit http://www.nanostring.com.
Vice President, Investor Relations & Corporate Communications
News Provided by Acquire Media